Clinical trial · no report yet · Phase 1
NCT06905197
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- NCT06905197 ↗
- Recruiting
- Dizal Pharmaceuticals
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- DZD6008; Sunvozertinib
- Arms
- Experimental: Part A Dose Escalation monotherapy cohorts (20 mg once daily [QD]) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (40 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (60 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (90 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (120 mg QD) · Experimental
- Experimental: Part A Dose Escalation monotherapy cohorts (150 mg QD) · Experimental
- Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 1) · Experimental
- Experimental: Experimental: Part A Dose Escalation Combination cohorts (Combination dose 2) · Experimental
- Experimental: Part A Dose Escalation Combination cohorts (Combination dose 3) · Experimental
- Experimental: Part B Dose Expansion cohort A1 (selected dose 1) · Experimental
- Experimental: Experimental: Part B Dose Expansion cohort A2 (selected dose 2) · Experimental
- Experimental: Experimental: Part B Dose Expansion cohort B1 (selected dose 1) · Experimental
- Experimental: Experimental: Part B Dose Expansion cohort B2 (selected dose 2) · Experimental
- Enrollment
- 140 (estimated)
- Primary outcomes
- Part A: To assess safety and tolerability
- Part A: To assess safety and tolerability
- Part B: To assess anti-tumor activity
- Sponsor
- Dizal Pharmaceuticals
- Start
- May 13, 2025
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06905197 · updated Feb 27, 2026